Open Access
BIO Web Conf.
Volume 55, 2022
5th International Conference on Frontiers of Biological Sciences and Engineering (FBSE 2022)
Article Number 01007
Number of page(s) 4
Published online 21 November 2022
  • 2022. Cancer. [online] Available at: [Google Scholar]
  • National Cancer Institute. 2022. Types of Cancer Treatment. [online] Available at: [Google Scholar]
  • J. Couzin-Frankel, Breakthrough of the year 2013. Cancer immunotherapy, Science 342 (6165) (2013) 1432–1433. [Google Scholar]
  • Lu Zhe, Zhang Guojun, Yao Qunfeng, The progress in cancer immunotherapy targeting PD - 1/PD - L1 immune checkpoint. Modern Oncology, Mar. 2022, Vol. 30, No. 05, 927-930 [Google Scholar]
  • The Nobel Prize in Physiology or Medicine 2018. Nobel Prize Outreach AB 2022. [Google Scholar]
  • 2022. School of Medicine Awards 21st Keio Medical Science Prize: Keio University. [online] Available at: [Google Scholar]
  • Mahoney, K. M., Rennert, P. D., and Freeman, G. J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561–584. [CrossRef] [PubMed] [Google Scholar]
  • .Henghao Pan, Haiyan Yang, Yang Lu, Shengquan Hu, Yizhe Wu, Qiaojun He, Xiaowu Dong, Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 proteinprotein interaction or targeting PD-L1 protein degradation, European Journal of Medicinal Chemistry, Volume 213, 2021, 113-170. [Google Scholar]
  • Zak K. M., Grudnik P., Guzik K., Zieba B. J., Musielak B., Dömling A., Dubin G., Holak T. A. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016; 7: 30323-30335. [CrossRef] [PubMed] [Google Scholar]
  • Z. Fan, Y. Tian, Z. Chen, L. Liu, Q. Zhou, J. He, J. Coleman, C. Dong, N. Li, J. Huang, C. Xu, Z. Zhang, S. Gao, P. Zhou, K. Ding, L. Chen, Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors, EMBO Mol. Med. 12 (6) (2020), e11571. [Google Scholar]
  • Ryan L. Setten, John J. Rossi, Si-ping Han, The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discovery, 2019, 18(6): 421446. [Google Scholar]
  • Takuro Horii, Izuho Hatada. Genome engineering using the CRISPR/Cas system. World Journal of Medical Genetics, 2014 August 27; 4(3): 69-76 [CrossRef] [Google Scholar]
  • Chen, W., Huang, Y., Pan, W., Xu, M. and Chen, L., 2022. Strategies for developing PD-1 inhibitors and future directions. Biochemical Pharmacology, 202, p.115113. [CrossRef] [PubMed] [Google Scholar]
  • Liu Y, Pan Y, Cao W, Xia F, Liu B, Niu J, Alfranca G, Sun X, Ma L, de la Fuente JM, Song J, Ni J, Cui D. A tumor microenvironment responsive biodegradable CaCO3/MnO2-based nanoplatform for the enhanced photodynamic therapy and improved PD-L1 immunotherapy. Theranostics. 2019 Sep 21;9(23):6867-6884. [CrossRef] [PubMed] [Google Scholar]
  • Zou, W., Wolchok, J. and Chen, L., 2016. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 8(328). [CrossRef] [Google Scholar]
  • Guo L, Wei R, Lin Y and Kwok HF (2020) Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment— Current Progress, Strategy, and Future Perspective. Front. Immunol. 11:1508. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.